Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt exercised stock options and sold the resulting shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options at an exercise price of $146.03 per share on March 2, 2026.
• Immediately following the exercise, Rothblatt sold all 9,500 acquired shares of common stock in multiple transactions on March 2, 2026.
• The sales occurred at weighted average prices ranging from $507.2669 to $525.28 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, Rothblatt directly owns 130 shares of common stock and indirectly owns 381,193 shares through various family trusts.
• Rothblatt also beneficially owns 230,500 derivative stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the pre-arranged 10b5-1 plan makes it a routine, expected transaction for executive compensation and diversification, rather than a signal of negative sentiment towards the company.

Positives

• The exercise of stock options at $146.03 and subsequent sale at prices over $500 indicates a significant profit for the reporting person, reflecting past stock appreciation.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which demonstrates a structured approach to insider stock sales and can mitigate concerns about opportunistic selling.

Negatives

• The sale of 9,500 shares by a key executive, even under a 10b5-1 plan, represents a reduction in direct insider ownership.

Future Outlook

The pre-arranged 10b5-1 trading plan, adopted on November 7, 2025, is set to continue until the earlier of the exercise of 1,734,410 stock options (which expire on March 17, 2027) or December 31, 2026, indicating a structured approach to future option exercises and share sales by the CEO.

Industry Context

StockSavvy.ai notes that executive stock option exercises and subsequent sales under Rule 10b5-1 plans are common practices in the biotechnology and pharmaceutical industries, allowing executives to diversify their holdings and manage tax liabilities in a pre-scheduled, compliant manner. This type of transaction is generally viewed as routine and not indicative of a change in the company's fundamental prospects, especially when executed under a pre-established plan.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO could be perceived as a slight negative due to reduced direct insider ownership, but the 10b5-1 plan mitigates concerns about opportunistic selling. The profitable exercise of options highlights the value created for long-term shareholders.

Next Steps

• The 10b5-1 trading plan will continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial planning and diversification, not a reflection of new material information about the company's prospects. Therefore, it does not provide a basis for changing an investment thesis, warranting a 'hold' recommendation.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, SEC Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, Executive Compensation, Biotechnology